Τρίτη 4 Απριλίου 2017

AACR 2017: Adding IDO inhibition to pembrolizumab improved response rate in melanoma

Adding the investigational immunotherapy indoximod to the FDA-approved immunotherapy pembrolizumab increased the proportion of patients with advanced melanoma who responded to treatment compared with previously reported response rates for pembrolizumab...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oxgbtz
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις